Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Mar;104(5):407-415.
doi: 10.1136/heartjnl-2017-311652. Epub 2017 Aug 5.

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Sean Lee Zheng  1   2   3 , Fiona T Chan  3 , Adam A Nabeebaccus  1   2 , Ajay M Shah  1   2 , Theresa McDonagh  1   2 , Darlington O Okonko  1   2 , Salma Ayis  4
Affiliations
Meta-Analysis

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Sean Lee Zheng et al. Heart. 2018 Mar.

Abstract

Background: Clinical drug trials in patients with heart failure and preserved ejection fraction have failed to demonstrate improvements in mortality.

Methods: We systematically searched Medline, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCT) assessing pharmacological treatments in patients with heart failure with left ventricular (LV) ejection fraction≥40% from January 1996 to May 2016. The primary efficacy outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, heart failure hospitalisation, exercise capacity (6-min walk distance, exercise duration, VO2 max), quality of life and biomarkers (B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide). Random-effects models were used to estimate pooled relative risks (RR) for the binary outcomes, and weighted mean differences for continuous outcomes, with 95% CI.

Results: We included data from 25 RCTs comprising data for 18101 patients. All-cause mortality was reduced with beta-blocker therapy compared with placebo (RR: 0.78, 95%CI 0.65 to 0.94, p=0.008). There was no effect seen with ACE inhibitors, aldosterone receptor blockers, mineralocorticoid receptor antagonists and other drug classes, compared with placebo. Similar results were observed for cardiovascular mortality. No single drug class reduced heart failure hospitalisation compared with placebo.

Conclusion: The efficacy of treatments in patients with heart failure and an LV ejection fraction≥40% differ depending on the type of therapy, with beta-blockers demonstrating reductions in all-cause and cardiovascular mortality. Further trials are warranted to confirm treatment effects of beta-blockers in this patient group.

Keywords: diastolic dysfunction; heart failure; meta-analysis; mid-range ejection fraction; preserved ejection fraction; systematic review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow diagram of the trial selection process. LVEF, left ventricular ejection fraction.
Figure 2
Figure 2
Pooled and individual estimates of relative risk (RR) and 95% CI of the primary outcome all-cause mortality for different therapies. Data are shown stratified by individual drug classes (beta-blockers, ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and other drug classes). Random-effects model used.
Figure 3
Figure 3
Pooled and individual estimates of relative risk (RR) and 95% CIs of the secondary outcome cardiovascular mortality for different therapies. Data are shown stratified by individual class blockers (beta-blockers, ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and other drug classes). Random-effects model used.
Figure 4
Figure 4
Pooled and individual estimates of relative risk (RR) and 95% CI of the secondary outcome heart failure hospitalisation for different therapies. Data are shown stratified by individual class blockers (beta-blockers, ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and other drug classes). Random-effects model used.
See this image and copyright information in PMC

Comment in

References

    1. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the european Society of Cardiology (ESC)Developed with the special contribution of the Heart failure association (HFA) of the ESC. European heart journal 2016. (Epub ahead of print). - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239. 10.1016/j.jacc.2013.05.019 - DOI - PubMed
    1. Holland DJ, Kumbhani DJ, Ahmed SH, et al. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol 2011;57:1676–86. 10.1016/j.jacc.2010.10.057 - DOI - PubMed
    1. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014;64:2281–93. 10.1016/j.jacc.2014.08.036 - DOI - PMC - PubMed
    1. Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014;35:2797–815. 10.1093/eurheartj/ehu204 - DOI - PMC - PubMed

Publication types

MeSH terms